Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. We are worldwide leaders in the development of a proprietary technology platform that enables specific regulation of gene expression and gene modification. The basis of this platform is a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs) which we can engineer to drive desired therapeutic outcomes. Engineered ZFPs can be linked to functional domains that normally activate or repress gene expression to create ZFP transcription factors (ZFP TFs) capable of turning genes on or off. We can also link ZFPs to nuclease domains to create zinc finger nucleases (ZFNs) which enable precise gene-editing in cells. Engineered ZFNs can modify a cell's DNA at a precise location, thereby facilitating correction or disruption of a specific gene or the targeted addition of a new DNA sequence.

Research Grants 24 show all


$104K
2004

$100K
2006

$5.7M
2009

$1.6M
2015

$1.3M
2017

Publications 149 show all

  • 21
    Zinc Fingers
  • 10
    Gene Expression Regulation
  • 10
    Zinc Fingers/genetics
  • 9
    Transcription Factors/genetics
  • 8
    Gene Targeting/methods
  • 8
    Genetic Therapy/methods
  • 8
    Transcription Factors/metabolism
  • 7
    Genome
  • 6
    Chromatin/genetics
  • 5
    Chromatin/metabolism

Patents 1,402show all

  • 593
    C12N - Microorganisms or enzymes
  • 464
    C07K - Peptides
  • 294
    A61K - Preparations for medical, dental, or toilet purposes
  • 126
    C12Y - Enzymes
  • 123
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 80
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 65
    A01K - Animal husbandry
  • 47
    G16B - Bioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology
  • 23
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture
  • 13
    C40B - Combinatorial chemistry

Clinical Trials 23show all

10Phase 1/Phase 27Phase 16Phase 2

SEC Filings show all


169
8-K

60
10-Q

19
10-K

1
S-1

Contact Information

Point Richmond Tech Center II 501 Canal Blvd
Richmond, CA 94804
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$93,200,000251-5002018-04-27Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2018-04-27$8,000,000GrantCalifornia Institute for Regenerative Medicine
2018-02-07$11,000,000GrantNational Institutes of Health
2013-09-24$74,200,000Post Ipo Equity